• 8:30 - 18:00 M-T / 8.30 - 15.00 F

HC016 Acute Pulmonary Disease


The HC016 platform is a treatment of acute lung injury, based on mesenchymal stem cells derived from adipose tissue (ASC), improved with proprietary Histocell technology.
hc016-lung

Innovation

HC016 cells modulate the inflammatory process by releasing specific enzymes and growth factors.

Development stage

"In vivo" Poc study finished with promising results.

"In vivo" Safety regulatory study finished with good safety profile.

Design of the Clinical Study phase I/II in acute respiratory distress will be submitted for IND approval by the AEMPS in June 2019.

Histocell

Histocell, S.L.
Parque Tecnológico 801A, 2º
48160 Derio
Bizkaia - Spain

+34 94 656 7900
info@histocell.com
www.histocell.com

Our values

We develop new healthcare products and cell therapy drugs to improve people's quality of life.

Copyright © Histocell